Monday, Apr 23, 1984

Genentech Expands Its Patent Department

South San Francisco, Calif. -- April 23, 1984 --

Walter E. Buting, Ph.d. a recognized leader in patent matters affecting biotechnology, has joined Genentech as chief patent counsel responsible for patents, trademarks and licensing. Max D. Hensley, another experienced patent attorney, has joined Genentech as senior patent counsel. "The addition of these key experts is a strong indication of the importance Genentech places on patents," said Robert A. Swanson, president and chief executive officer. "As we approach the marketplace, we expect our products to be well protected by patents. We will also have the capability to enforce those patents, where required to prevent others from capitalizing on our investment in pioneering research."

Dr. Buting, 60, was formerly Eli Lilly and Company's patent counsel for biochemical products as well as licensing counsel. Responsibilities included all licensing as well as patents in the antibiotic, polypeptide and biotechnology fields. At Eli Lilly for 32 years, Dr. Buting also held positions as a research chemist, patent attorney, assistant patent counsel and patent counsel for chemical products before focusing on biochemical patent matters six years ago. He holds a Ph.D. in organic chemistry from Purdue University and a J.D. from Indiana University School of Law.

Mr. Hensley, 37, who also has focused on biochemical patent matters, was a divisional patent attorney for nine years at Travenol Laboratories. He handled all phases of patent practice, including patent application preparation and prosecution, licensing and contracts. Previously he was a patent examiner at the United States Patent and Trademark Office and more recently a patent attorney at the United States Department of Agriculture. He holds a B.S. in Biochemistry from the University of Wisconsin and a J.D. from George Washington Unversity School of Law.

Genentech, Inc. is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology. Principal human and animal health care products in the development include: human growth hormone for the treatment of short stature due to growth hormone deficiency; human gamma interferon for anti-cancer and anti-viral indications; tissue-type plasminogen activator for dissolving blood clots in victims of heart attacks and other cardiovascular disorders; and bovine interferon for protection of cattle against Bovine Respiratory Disease ("shipping fever").

# # #